- Home
- NVO vs GILD Comparison
NVO vs GILD Comparison
Compare NVO & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVO | GILD |
|---|---|---|
| Founded | 1923 | 1987 |
| Country | Denmark | United States |
| Employees | 69500 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.5B | 184.4B |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | NVO | GILD |
|---|---|---|
| Price | $36.53 | $139.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 18 |
| Target Price | $51.00 | ★ $146.50 |
| AVG Volume (30 Days) | ★ 14.0M | 5.0M |
| Earning Date | 05-06-2026 | 04-23-2026 |
| Dividend Yield | ★ 3.48% | 2.35% |
| EPS Growth | N/A | ★ 1684.21 |
| EPS | N/A | ★ 6.78 |
| Revenue | N/A | ★ $24,689,000,000.00 |
| Revenue This Year | N/A | $4.65 |
| Revenue Next Year | $3.30 | $5.96 |
| P/E Ratio | ★ $13.60 | $20.61 |
| Revenue Growth | N/A | ★ 9.98 |
| 52 Week Low | $35.12 | $95.30 |
| 52 Week High | $81.44 | $157.29 |
Technical Indicators
Market Signals| Indicator | NVO | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 38.52 | 47.28 |
| Support Level | $35.85 | $108.90 |
| Resistance Level | $37.44 | $149.38 |
| Average True Range (ATR) | 0.94 | 3.30 |
| MACD | 0.45 | 0.04 |
| Stochastic Oscillator | 36.87 | 48.48 |
Price Performance
Historical ComparisonAbout NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).